Chief Business Officer
Brett Huselton serves as Senior Vice President & Chief Business Officer at UBC. Brett joined UBC in 2008 and has greater than 20 years in the pharmaceutical services industry from early development through late phase development, globally – supporting strategy and business development growth strategies across clinical and late stage, through commercially optimized launch strategies.
In this role, Brett is responsible for Sales, Marketing, Business Strategy, Product Development, Proposal Development, Pricing and Connected Healthcare Technologies, as well as Analytics and Insights. Brett is responsible to align UBC’s deep bench of expertise, product and service solutions to address the development, safety, access, affordability and value demands facing our clients as they navigate regulatory, payer, physician and patient demands for a successful initial and ongoing experience with their therapy.
Brett and his teams focus on a deep understanding of the market, regulatory and legislative initiatives, payer and managed market demands to ensure our proposed solutions address the specific demands of our clients – whether in the pre-market setting, as they capture evidence of efficacy, effectiveness and safe use – all the way through supporting their approach to entering the market, establishing an ideal patient access, affordability or clinical coordination program to ensure access to and success on our customers therapy.
Importantly – as the market dynamics change, Brett’s teams are focused heavily on trends that impact the efficiency of the delivery of work, or, impact the evidence generation strategies required to meet both clinical and commercial objectives as our clients define their ideal product label and target market.
Brett and UBC focus on making meaningful decisions related to impacting the transformation and advancement of patient care through investing in new approaches, tools, data standards and technologies that can streamline acquisition of key data (endpoints), take advantage of advancements in the interoperability between systems being promoted externally across health systems, payers, data providers and pharma – as well as modeling and following the patient journey from clinical research encounters through to commercial care to truly point the market to a more value-driven conversation about a product’s safe use, patient-specific benefit, humanistic & clinical value proposition of the data across both individual Patients and larger real-world populations.